Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
Rhea-AI Summary
Telix (ASX/NASDAQ: TLX) will present a pipeline and commercial-portfolio overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Dr. Christian Behrenbruch, Managing Director and Group CEO, will present on Monday, 12 January 2026 at 9:00 am PST (12:00 pm EST / 4:00 am AEDT, 13 January). The presentation will be webcast live and available on demand for 30 days via the company Investor Relations website. Telix will also publish a dedicated presentation detailing all therapeutic pipeline assets. Telix plans to release Q4 2025 financials on 20 January 2026.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TLX gained 1.73%, reflecting a mild positive market reaction. This price movement added approximately $43M to the company's valuation, bringing the market cap to $2.51B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: RARE +5.86%, APLS +10.28%, LGND +1.29%, MLTX +0.18%, ZLAB -0.57%. With TLX up 0.54% and no peers in momentum scanners, today’s action appears stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 21 | Clinical portfolio update | Positive | +3.2% | Phase 3 Illuccix China success and multiple FDA-related resubmission updates. |
| Dec 10 | Strategic collaboration | Positive | +3.1% | Theranostics-EBRT clinical collaboration framework with Varian across PET candidates. |
| Nov 19 | Clinical trial data | Positive | -1.5% | ZIRCON-X analysis showing TLX250-CDx altered management in many renal mass cases. |
| Nov 05 | Investor conferences | Positive | +0.1% | Participation in UBS and Jefferies healthcare conferences with webcast access. |
| Oct 23 | Guideline inclusion | Positive | +0.9% | TLX250-CDx added to major renal imaging guidelines citing strong sensitivity/specificity. |
Recent positive clinical and collaboration updates have usually seen modestly positive price reactions, with one divergence on favorable clinical data.
Over the last few months, Telix has reported several clinical and strategic milestones. On Oct 23, 2025, TLX250-CDx guideline inclusion followed strong ZIRCON data. Subsequent ZIRCON-X results on Nov 19, 2025 showed meaningful clinical decision impact but saw a -1.53% move. A Varian theranostics-EBRT collaboration on Dec 10, 2025 and a precision medicine portfolio update on Dec 21, 2025 both coincided with ~3% gains. The current J.P. Morgan conference participation continues this pattern of active investor and clinical communication.
Market Pulse Summary
This announcement highlights Telix’s plan to showcase its pipeline and commercial portfolio at the J.P. Morgan Healthcare Conference and to release Q4 2025 financials on Jan 20, 2026. Set against prior clinical wins, strategic collaborations and strong Q2 revenue of US$240 million with 63% year-over-year growth, the event provides another structured touchpoint for investors to assess progress across precision imaging and therapeutics programs.
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.).
Telix will host a presentation on Monday, 12 January at 9:00 am PST (12:00 pm EST / 4:00 am AEDT, 13 January), providing an overview of the Company’s pipeline assets alongside its commercial portfolio.
The event will be webcast live here and available on demand for 30 days via the Telix Investor Relations website at: ir.telixpharma.com/
In addition to the live presentation and slides, Telix will publish a comprehensive overview of all therapeutic pipeline assets in a dedicated presentation accessible on the Investor Relations website.
Financials for the fourth quarter of 2025, will be released on 20 January, 2026.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
United States
Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-CDx and the planned BLA resubmission for TLX250-CDx, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
FAQ
When will Telix (TLX) present at the J.P. Morgan Healthcare Conference in 2026?
How can investors watch the Telix (TLX) presentation at J.P. Morgan 2026?
What will Telix (TLX) cover in its J.P. Morgan 2026 presentation?
Where will Telix post the on-demand presentation and slides for investors?
When will Telix (TLX) release its Q4 2025 financial results?
